CN1157189C - 半合成海鞘素 - Google Patents

半合成海鞘素 Download PDF

Info

Publication number
CN1157189C
CN1157189C CNB998070769A CN99807076A CN1157189C CN 1157189 C CN1157189 C CN 1157189C CN B998070769 A CNB998070769 A CN B998070769A CN 99807076 A CN99807076 A CN 99807076A CN 1157189 C CN1157189 C CN 1157189C
Authority
CN
China
Prior art keywords
compd
ascidin
excipient
semi
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998070769A
Other languages
English (en)
Chinese (zh)
Other versions
CN1304309A (zh
Inventor
Kl
K·L·莱恩哈特
��Ī������
J·J·莫拉莱斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of CN1304309A publication Critical patent/CN1304309A/zh
Application granted granted Critical
Publication of CN1157189C publication Critical patent/CN1157189C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Dental Preparations (AREA)
CNB998070769A 1998-04-06 1999-04-05 半合成海鞘素 Expired - Fee Related CN1157189C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8080298P 1998-04-06 1998-04-06
US60/080,802 1998-04-06

Publications (2)

Publication Number Publication Date
CN1304309A CN1304309A (zh) 2001-07-18
CN1157189C true CN1157189C (zh) 2004-07-14

Family

ID=22159716

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998070769A Expired - Fee Related CN1157189C (zh) 1998-04-06 1999-04-05 半合成海鞘素

Country Status (27)

Country Link
US (1) US6124293A (enExample)
EP (2) EP1067933B1 (enExample)
JP (1) JP4443043B2 (enExample)
KR (1) KR100603219B1 (enExample)
CN (1) CN1157189C (enExample)
AT (1) ATE370148T1 (enExample)
AU (1) AU758100B2 (enExample)
BG (1) BG65088B1 (enExample)
BR (1) BR9909488B1 (enExample)
CA (1) CA2327468C (enExample)
CY (1) CY1106988T1 (enExample)
CZ (1) CZ301083B6 (enExample)
DE (1) DE69936845T2 (enExample)
DK (1) DK1067933T3 (enExample)
ES (1) ES2292237T3 (enExample)
HU (1) HUP0104273A3 (enExample)
IL (2) IL138856A0 (enExample)
MX (1) MXPA00009840A (enExample)
NO (1) NO328147B1 (enExample)
NZ (1) NZ507350A (enExample)
PL (1) PL196809B1 (enExample)
PT (1) PT1067933E (enExample)
RU (1) RU2217432C2 (enExample)
SK (1) SK285669B6 (enExample)
TR (1) TR200002921T2 (enExample)
UA (1) UA59439C2 (enExample)
WO (1) WO1999051238A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
IL139607A0 (en) * 1998-05-11 2002-02-10 Pharma Mar Sa Metabolites of ecteinascidin 743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
EP1254140A4 (en) 2000-01-19 2003-03-12 Univ Columbia SAFRAMYCIN-ECTEINASCIDIN SERIES COMPOUNDS, USAGE AND SYNTHESIS THEREOF
US7919493B2 (en) * 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
JP2004529074A (ja) 2000-11-03 2004-09-24 プレジデント アンド フェロウズ オブ ハーバード カレッジ サフラマイシン、そのアナログ、およびその使用
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CN100355775C (zh) * 2006-01-20 2007-12-19 南方医科大学 一种海鞘多肽及其制备方法
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
EP2786755A3 (en) 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
RU2738741C2 (ru) * 2016-02-04 2020-12-16 Цзянсу Хэнжуй Медицин Ко., Лтд. Инъекционная фармацевтическая композиция, включающая трабектедин, для применения вне желудочно-кишечного тракта и способ её получения
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
CA3158733A1 (en) 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
TW221441B (enExample) * 1991-01-25 1994-03-01 Taiho Pharmaceutical Co Ltd
US5440055A (en) * 1993-03-12 1995-08-08 Aphios Corporation Method and apparatus for extracting taxol from source materials
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds

Also Published As

Publication number Publication date
CZ20003650A3 (en) 2001-06-13
KR20010074474A (ko) 2001-08-04
HUP0104273A2 (hu) 2002-03-28
ATE370148T1 (de) 2007-09-15
BG104902A (en) 2001-07-31
JP4443043B2 (ja) 2010-03-31
BR9909488A (pt) 2000-12-26
AU3471399A (en) 1999-10-25
JP2002510633A (ja) 2002-04-09
CZ301083B6 (cs) 2009-11-04
DK1067933T3 (da) 2007-12-27
SK285669B6 (sk) 2007-06-07
NO20004978L (no) 2000-12-05
IL138856A0 (en) 2001-10-31
HK1033651A1 (en) 2001-09-14
NO20004978D0 (no) 2000-10-03
EP1067933A1 (en) 2001-01-17
HUP0104273A3 (en) 2003-12-29
DE69936845T2 (de) 2008-05-08
CA2327468C (en) 2008-05-06
AU758100B2 (en) 2003-03-13
CA2327468A1 (en) 1999-10-14
RU2217432C2 (ru) 2003-11-27
PL343439A1 (en) 2001-08-13
US6124293A (en) 2000-09-26
CY1106988T1 (el) 2012-09-26
EP1876180A2 (en) 2008-01-09
DE69936845D1 (de) 2007-09-27
RU2000128058A (ru) 2004-02-20
KR100603219B1 (ko) 2006-07-20
WO1999051238A1 (en) 1999-10-14
ES2292237T3 (es) 2008-03-01
PL196809B1 (pl) 2008-02-29
EP1067933B1 (en) 2007-08-15
NO328147B1 (no) 2009-12-21
NZ507350A (en) 2003-03-28
CN1304309A (zh) 2001-07-18
MXPA00009840A (es) 2002-04-24
BR9909488B1 (pt) 2011-02-08
EP1067933A4 (en) 2002-12-18
IL138856A (en) 2007-07-24
WO1999051238A9 (en) 2000-01-27
BG65088B1 (bg) 2007-02-28
EP1876180A3 (en) 2009-12-16
PT1067933E (pt) 2007-11-15
TR200002921T2 (tr) 2001-02-21
UA59439C2 (uk) 2003-09-15
SK15012000A3 (sk) 2001-08-06

Similar Documents

Publication Publication Date Title
CN1304309A (zh) 半合成海鞘素
EP1117297B1 (en) Synthetic analogs of ecteinascidin-743
CN100343235C (zh) 亲和取代的海鞘素和n－氧化海鞘素
FI110941B (fi) Menetelmä terapeuttisesti käyttökelpoisten 7,8-metyleenitaksoidien valmistamiseksi ja välituotteita
HUP0300534A2 (hu) Tumorellenes ekteinaszcidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
US6569859B1 (en) Synthetic analogs of ecteinascidin-743
CN1154652C (zh) 5-亚氨基-13-脱氧蒽环素衍生物,其用途及其制备方法
JP2000510450A (ja) 群体ホヤ類のリッソクリヌム種からの環状ヘプタ―ペプチド誘導体
CN1087018C (zh) 新的二－吡啶并[4,3－b]咔唑化合物、其制备方法以及含有它们的药物组合物
AU2001233873A1 (en) Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
CN1580057A (zh) 20(s)－喜树碱衍生物、其制备方法及用途
HK1033651B (en) Semi-synthetic ecteinascidins
EP1255746A1 (en) Oxy- and amino-substituted tetrahydrofuryl derivatives with antimour activity
JPH1045763A (ja) 新規化合物および抗腫瘍剤
JP2001527076A (ja) 海綿動物から単離されるアスマリンａ及びｂを含む細胞毒性アルカロイド誘導体
JPH07116193B2 (ja) 新規な抗腫瘍性化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040714

Termination date: 20110405